Celator(R) Pharmaceuticals Initiates Pharmacokinetic and Pharmacodynamics Clinical Study of CPX-351
August 19, 2014 08:30 ET
|
Celator Pharmaceuticals, Inc.
EWING, N.J., Aug. 19, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that...
Celator(R) Pharmaceuticals Announces Business Update and Second Quarter 2014 Financial Results
August 07, 2014 16:01 ET
|
Celator Pharmaceuticals, Inc.
EWING, N.J., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today reported business...
Celator(R) Pharmaceuticals to Report Second Quarter 2014 Financial Results on August 7, 2014
July 31, 2014 08:30 ET
|
Celator Pharmaceuticals, Inc.
EWING, N.J., July 31, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc., (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that...
Celator(R) Pharmaceuticals Provides Update on CPX-351 and Technology Platform at Analyst Day
July 17, 2014 08:00 ET
|
Celator Pharmaceuticals, Inc.
New Applications Announced for Proprietary CombiPlex Platform Geared Towards Molecularly Targeted Therapies
CPX-351 to be Explored in Additional Patient Populations, Including New Acute...
Celator(R) Pharmaceuticals Announces Analyst Day and Webcast
July 02, 2014 08:30 ET
|
Celator Pharmaceuticals, Inc.
EWING, N.J., July 2, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that...
Celator(R) Pharmaceuticals to be Added to Russell MicroCap Index
June 27, 2014 08:30 ET
|
Celator Pharmaceuticals, Inc.
EWING, N.J., June 27, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, announced that...
Celator(R) Pharmaceuticals to Present at Upcoming Conferences in June
June 17, 2014 16:30 ET
|
Celator Pharmaceuticals, Inc.
EWING, N.J., June 17, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that...
Celator(R) Pharmaceuticals Announces Data and Safety Monitoring Board Recommendation to Continue Phase 3 Study of CPX-351
June 11, 2014 08:30 ET
|
Celator Pharmaceuticals, Inc.
EWING, N.J., June 11, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that...
Celator(R) Pharmaceuticals Reaches 75% Enrollment Milestone in Phase 3 Study of CPX-351
June 04, 2014 08:30 ET
|
Celator Pharmaceuticals, Inc.
EWING, N.J., June 4, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it...
Celator(R) Pharmaceuticals Announces Publication of Positive Phase 2 Data With CPX-351 in Acute Myeloid Leukemia Patients
May 27, 2014 08:30 ET
|
Celator Pharmaceuticals, Inc.
EWING, N.J., May 27, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), announced the publication of the Phase 2 study evaluating CPX-351 in newly diagnosed older patients with...